Public Employees Retirement System of Ohio Acquires New Stake in Roivant Sciences Ltd. $ROIV

Posted by Brenda Bartman on Sep 3rd, 2026

Public Employees Retirement System of Ohio bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) in the second quarter, HoldingsChannel.com reports. The firm bought 139,481 shares of the company’s stock, valued at approximately $4,936,000.

A number of other large investors have also recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its holdings in shares of Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after buying an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. raised its position in Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after buying an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp raised its position in Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after buying an additional 1,181 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $41.00 price target on shares of Roivant Sciences in a research report on Friday, August 28th. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Get Our Latest Stock Report on ROIV

Roivant Sciences Stock Down 1.0%

NASDAQ:ROIV opened at $34.18 on Thursday. Roivant Sciences Ltd. has a twelve month low of $12.28 and a twelve month high of $37.97. The firm has a market capitalization of $24.69 billion, a price-to-earnings ratio of -64.49 and a beta of 1.12. The stock’s 50 day moving average price is $35.27 and its two-hundred day moving average price is $31.09.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. As a group, analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Insider Activity

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director directly owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 144,756 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the transaction, the insider owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. This trade represents a 0.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 3,055,913 shares of company stock worth $107,261,258. 8.80% of the stock is owned by insiders.

Roivant Sciences Company Profile

(Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.